Positions

Overview

  • Strategies for hematopoietic stem cell transplantation in chronic lymphoproliferative disorders. Toxicity of hematopoietic stem cell transplantation. Population outcomes of hematologic malignancies.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Challenges and opportunities in the assessment of measurable residual disease in multiple myelomaCirculation: Heart Failure.  186:807-819. 2019
    2019 Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell TransplantationJournal of applied physiology: respiratory, environmental and exercise physiology.  25:1744-1755. 2019
    2019 Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapyLeukemia.  33:2266-2275. 2019
    2019 Oral selinexor-dexamethasone for triple-class refractory multiple myelomaNew England Journal of Medicine.  381:727-738. 2019
    2019 Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivorsLeukemia Research.  82:1-6. 2019
    2019 LEAM versus CBV for conditioning in autologous hematopoietic stem cell transplantation for lymphomamSystems.  54:625-628. 2019
    2019 Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of originLeukemia & Lymphoma.  60:940-946. 2019
    2019 Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER studyLeukemia & Lymphoma.  60:894-903. 2019
    2019 Incidence and outcomes of rare paediatric non-hodgkin lymphomasCirculation: Heart Failure.  184:864-867. 2019
    2019 The Future of Chimeric Antigen Receptor T Cell Therapy for the Treatment of Multiple MyelomaJournal of applied physiology: respiratory, environmental and exercise physiology.  25:e73-e75. 2019
    2019 Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost ImplicationsJournal of applied physiology: respiratory, environmental and exercise physiology.  25:233-238. 2019
    2019 Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic TransplantationJournal of applied physiology: respiratory, environmental and exercise physiology.  25:73-85. 2019
    2019 Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune ProfilingJournal of applied physiology: respiratory, environmental and exercise physiology2019
    2019 Up-front autologous hematopoietic stem cell transplantation (AHSCT) from a single Brazilian centermSystems2019
    2018 Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrowLeukemia Research.  74:64-67. 2018
    2018 A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801Haematologica.  103:1915-1924. 2018
    2018 Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplantmSystems.  53:1345-1348. 2018
    2018 Second primary malignancy after multiple myeloma-population trends and cause-specific mortalityCirculation: Heart Failure.  182:513-520. 2018
    2018 Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple MyelomaJournal of applied physiology: respiratory, environmental and exercise physiology.  24:1379-1385. 2018
    2018 Incidence and survival trends in mantle cell lymphomaCirculation: Heart Failure.  181:703-706. 2018
    2018 Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow TransplantationJournal of applied physiology: respiratory, environmental and exercise physiology.  24:909-913. 2018
    2018 Infectious diarrhea in autologous stem cell transplantation: high prevalence of coccidia in a South American centerHematology, Transfusion and Cell Therapy.  40:132-135. 2018
    2018 Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: Final results from the PILLAR-2 randomized phase III trialJournal of Clinical Neurology (Seoul, Korea).  29:707-714. 2018
    2018 Incidence and outcomes of paediatric myelodysplastic syndrome in the United StatesCirculation: Heart Failure.  180:898-901. 2018
    2018 Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adultsJournal of Clinical Orthopaedics and Trauma.  93:238-245. 2018
    2018 R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysisCirculation: Heart Failure.  180:534-544. 2018
    2018 Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myelomaJournal of Clinical Oncology.  36:859-866. 2018
    2017 Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: A center for international blood and marrow transplant research analysismSystems.  52:1616-1622. 2017
    2017 Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” studyHematological Oncology.  35:528-535. 2017
    2017 C-MYC–positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapyBasic Research in Cardiology, Supplement.  123:4411-4418. 2017
    2017 Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR reportBasic Research in Cardiology, Supplement.  123:3141-3149. 2017
    2017 Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapiesJournal of Clinical Orthopaedics and Trauma.  92:161-170. 2017
    2017 Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple MyelomaJournal of applied physiology: respiratory, environmental and exercise physiology.  23:269-277. 2017
    2017 Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United StatesAmerican Journal of Clinical Nutrition.  1:282-287. 2017
    2016 Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validityLeukemia & Lymphoma.  57:2827-2832. 2016
    2016 Impact of marital status, insurance status, income, and race/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United StatesBasic Research in Cardiology, Supplement.  122:3183-3190. 2016
    2016 Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-makingJournal of Clinical Orthopaedics and Trauma.  91:1044-1051. 2016
    2016 Mobilization of hematopoietic progenitor cells for autologous transportation: Consensus recommendationsRevista da Associação Médica Brasileira.  62:10-15. 2016
    2016 Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignanciesCirculation: Heart Failure.  175:55-65. 2016
    2016 Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older PatientsJournal of applied physiology: respiratory, environmental and exercise physiology.  22:1543-1551. 2016
    2016 Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recoveryJournal of Hematology & Oncology.  9. 2016
    2016 Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR OutcomesJournal of applied physiology: respiratory, environmental and exercise physiology.  22:1197-1205. 2016
    2016 Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndromeJournal of Clinical Oncology.  34:1864-1871. 2016
    2016 Reply to a note on the magnitude of hazard ratiosBasic Research in Cardiology, Supplement.  122:1299-1300. 2016
    2016 Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case ForumJournal of applied physiology: respiratory, environmental and exercise physiology.  22:564-570. 2016
    2016 Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical featuresPhysician Executive.  27:81-91. 2016
    2016 Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myelomaJournal of Clinical Orthopaedics and Trauma.  91:101-108. 2016
    2015 Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myelomaLeukemia & Lymphoma.  56:3320-3328. 2015
    2015 Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantationmSystems.  50:1513-1518. 2015
    2015 Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A center for international blood and marrow transplant research studyJournal of Clinical Oncology.  33:3741-3749. 2015
    2015 A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphomamSystems.  50:1416-1423. 2015
    2015 Nonbiological factors affecting survival in younger patients with acute myeloid leukemiaBasic Research in Cardiology, Supplement.  121:3877-3884. 2015
    2015 The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning RegimenJournal of applied physiology: respiratory, environmental and exercise physiology.  21:1746-1753. 2015
    2015 Early mortality in multiple myelomaLeukemia.  29:1616-1618. 2015
    2015 Fewer scans, better careJournal of Clinical Oncology.  33:1624. 2015
    2015 Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donormSystems.  50:197-203. 2015
    2015 Changes in the use of radiation therapy for early classical Hodgkin lymphoma in adolescents and young adults: Implications for survival and second malignanciesLeukemia & Lymphoma.  56:2339-2343. 2015
    2015 Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body IrradiationJournal of applied physiology: respiratory, environmental and exercise physiology.  21:552-558. 2015
    2015 Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myelomaJournal of applied physiology: respiratory, environmental and exercise physiology.  21:701-706. 2015
    2015 Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow TransplantationJournal of applied physiology: respiratory, environmental and exercise physiology.  21:1155-1166. 2015
    2015 Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-hodgkin lymphomaJournal of education for social work.  22:87-94. 2015
    2015 Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myelomaCirculation: Heart Failure.  169:219-227. 2015
    2015 REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemiaCirculation: Heart Failure.  168:796-805. 2015
    2015 Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphomaLeukemia & Lymphoma.  56:645-649. 2015
    2014 Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myelomaJournal of Health Psychology.  124:1915-1925. 2014
    2014 Lomustine use in combination with etoposide, cytarabine and melphalan in a brief conditioning regimen for auto-HSCT in patients with lymphoma: the optimal dosemSystems.  49:1239-1240. 2014
    2014 Optimizing autologous stem cell mobilization strategies to improve patient outcomes: Consensus guidelines and recommendationsJournal of applied physiology: respiratory, environmental and exercise physiology.  20:295-308. 2014
    2014 Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: Analysis of transplantation timing and modalityJournal of Clinical Oncology.  32:273-281. 2014
    2014 Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: Implications for risk-stratificationJournal of applied physiology: respiratory, environmental and exercise physiology.  20:222-228. 2014
    2014 Features and outcomes of diffuse large B-cell lymphoma of the thyroid in a large contemporary cohortLeukemia & Lymphoma.  55:283-287. 2014
    2014 Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myelomaJournal of applied physiology: respiratory, environmental and exercise physiology.  20:402-408.e1. 2014
    2014 Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular LymphomaJournal of applied physiology: respiratory, environmental and exercise physiology.  20:951-959. 2014
    2014 Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: Guidelines from the american society for blood and marrow transplantationJournal of applied physiology: respiratory, environmental and exercise physiology.  20:1262-1273. 2014
    2014 Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant ResearchJournal of applied physiology: respiratory, environmental and exercise physiology.  20:89-97. 2014
    2014 Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixaforTransfusion.  54:3131-3137. 2014
    2013 Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBIJournal of Health Psychology.  122:3863-3870. 2013
    2013 Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myelomaJournal of applied physiology: respiratory, environmental and exercise physiology.  19:1615-1624. 2013
    2013 Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivorsBasic Research in Cardiology, Supplement.  119:3385-3392. 2013
    2013 Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphomaJournal of Clinical Oncology.  31:3100-3109. 2013
    2013 Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: An analysis of 3691 casesJournal of Health Psychology.  121:4861-4866. 2013
    2013 Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: Meta-analysis of trials with biological assignmentmSystems.  48:562-567. 2013
    2013 Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and Marrow Transplant ResearchJournal of applied physiology: respiratory, environmental and exercise physiology.  19:173-179. 2013
    2012 Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patientsLeukemia & Lymphoma.  53:2444-2448. 2012
    2012 Growth factor plus preemptive (just-in-time) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposuremSystems.  47:1403-1408. 2012
    2012 Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchangeEuropean Journal of Haematology.  89:432-434. 2012
    2012 Pegfilgrastim-versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: Efficacy and cost analysisTransfusion.  52:2375-2381. 2012
    2011 Clonal diversity analysis using SNP microarray: A new prognostic tool for chronic lymphocytic leukemiaJournal of Pediatric Biochemistry.  204:654-665. 2011
    2011 Beyond CD34+ cell dose: Impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft functionTransfusion.  51:1995-2000. 2011
    2011 Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agentsJournal of Clinical Orthopaedics and Trauma.  86:699-701. 2011
    2011 Efficacy and Safety of Ciprofloxacin for Prophylaxis of Polyomavirus BK Virus-Associated Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplantation RecipientsJournal of applied physiology: respiratory, environmental and exercise physiology.  17:1176-1181. 2011
    2011 Alternative donor transplantation after reduced intensity conditioning: Results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood graftsJournal of Health Psychology.  118:282-288. 2011
    2011 Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilizationmSystems.  46:523-528. 2011
    2011 Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilizationmSystems.  46:64-69. 2011
    2010 Case report: Primary testicular lymphoma and AIDSJournal- Royal College of Surgeons Edinburgh.  40:75-79. 2010
    2010 Testicular lymphomaSeminars in Oncology.  37:549-554. 2010
    2010 Overcoming HLA-DPB1 donor specific antibody-mediated haematopoietic graft failureCirculation: Heart Failure.  151:94-96. 2010
    2010 Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenibCochrane Library.  103:796-801. 2010
    2010 Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitisJournal of Clinical Orthopaedics and Trauma.  85:627-629. 2010
    2010 Self-limited hemolysis due to anti-D passenger lymphocyte syndrome in allogeneic hematopoietic stem cell transplantationmSystems.  45:772-773. 2010
    2009 Impact of allogeneic haematopoietic stem cell transplantation in the outcome of Ph+ acute lymphoblastic leukaemia treated with an imatinib-containing regimenCirculation: Heart Failure.  146:576-577. 2009
    2009 Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myelomaLeukemia & Lymphoma.  50:781-787. 2009
    2008 Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphomaCirculation: Heart Failure.  143:268-273. 2008
    2008 Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantationCirculation: Heart Failure.  142:404-412. 2008
    2008 Autologous HSC transplant in t-MDS/AML using cells harvested prior to the development of the secondary malignancymSystems.  42:497-498. 2008
    2008 Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: Statistical analysis of all published cases and literature reviewJournal of Neonatology.  47:962-970. 2008
    2008 Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantationmSystems.  41:715-720. 2008
    2007 Renal cell carcinoma: New developments in molecular biology and potential for targeted therapiesOncologist.  12:1404-1415. 2007
    2007 Upstream Signaling Inhibition Enhances Rapamycin Effect on Growth of Kidney Cancer CellsUrology.  69:596-602. 2007
    2007 Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphomaAnnals of the New York Academy of Sciences.  33:78-84. 2007
    2006 Woman with a papillary pulmonary lesion and a complex renal cystOncology.  20. 2006
    2005 Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinomaCochrane Library.  92:2266-2277. 2005
    2005 Use of complementary and alternative medicine by Brazilian oncologistsEuropean Journal of Cancer Care.  14:143-148. 2005
    2005 Systemic chemotherapy induces microsatellite instability in the peripheral blood mononuclear cells of breast cancer patients.Ecological Psychology.  7. 2005
    2004 Simultaneous occurrence of Hodgkin disease and tuberculosis: Report of three casesSouthern Medical Journal.  97:696-698. 2004
    2004 Commentary: The quality of randomised controlled trials may be better than assumedJournal of Refractive Surgery.  328:24-25. 2004
    2004 Evaluation of non-oncologist physician's knowledge and attitude towards cancer screening and preventive actionsRevista da Associação Médica Brasileira.  50:257-262. 2004
    2004 Negative results in cancer clinical trials - Equivalence or poor accrual?Journal of receptor research.  25:525-533. 2004
    2003 White coat effect in breast cancer patients undergoing chemotherapyEuropean Journal of Cancer Care.  12:372-373. 2003
    1999 Pilot study of the combination of melphalan, carboplatin and etoposide as a conditioning regimen for relapsed lymphoma patientsNATO Science for Peace and Security Series B: Physics and Biophysics.  102:56-58. 1999
    1995 Main variations of the extrahepatic biliary system and their application to the so-called "split-liver" transplantation techniqueRevista do Hospital das Clínicas.  50:311-313. 1995

    Principal Investigator On

  • UAB 1815: Phase 2 Trial of Intensive Chemo-immu,otherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed.Refractory Myeloma In the context of Salvage Autologous Hematopoietic Cell Transplantation  awarded by Memorial Sloan-Kettering Cancer Center 2019 - 2024
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • International Myeloma Foundation Study of the Outcomes of Myeloma Patients with t(11;14) Translocation  awarded by International Myeloma Foundation 2019 - 2024
  • Private Grant  awarded by AMGEN, INC. 2018 - 2023
  • Private Grant  awarded by MUNDIPHARMA 2018 - 2023
  • Private Grant  awarded by JUNO THERAPEUTICS 2018 - 2023
  • Private Grant  awarded by CELGENE INTERNATIONAL II SÀRL 2018 - 2023
  • Private Grant  awarded by AMGEN, INC. 2018 - 2023
  • Private Grant  awarded by Janssen 2018 - 2023
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2022
  • IUAB 1677: Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma using Ibrutinib  awarded by VANDERBILT UNIVERSITY 2017 - 2022
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2017 - 2022
  • Private Grant  awarded by CELGENE CORPORATION 2017 - 2022
  • Private Grant  awarded by ABBVIE INC 2016 - 2021
  • Private Grant  awarded by KARYOPHARM THERAPEUTICS, INC. 2015 - 2020
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW 2018 - 2020
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2020
  • Private Grant  awarded by ONYX PHARMACEUTICALS, INC. 2015 - 2020
  • Private Grant  awarded by GlaxoSmithKline 2018 - 2019
  • UAB 1324 -- A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo-BM) for Patients with Hematologic Malignancies  awarded by National Marrow Donor Program 2016 - 2018
  • Private Grant  awarded by IMMUNOGEN, INC. 2017 - 2018
  • Investigator On

  • Multicenter Study of The Impact of Cytogenetic Abnormalities in Patients with Light Chain Amyloidosis  awarded by MAYO CLINIC 2019 - 2024
  • Private Grant  awarded by KITE PHARMA 2019 - 2024
  • Private Grant  awarded by MIRAGEN THERAPEUTICS INC. 2019 - 2024
  • Private Grant  awarded by Genentech 2019 - 2024
  • Private Grant  awarded by RHIZEN PHARMACEUTICALS SA 2018 - 2023
  • Private Grant  awarded by RHIZEN PHARMACEUTICALS SA 2018 - 2023
  • Private Grant  awarded by GlaxoSmithKline 2019 - 2023
  • Private Grant  awarded by Genentech 2018 - 2023
  • Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507  awarded by National Marrow Donor Program 2017 - 2023
  • Private Grant  awarded by PHARMACYCLICS, INC. 2018 - 2023
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS, INC. 2019 - 2022
  • A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML  awarded by National Marrow Donor Program 2017 - 2022
  • Private Grant  awarded by ADC THERAPEUTICS SA 2019 - 2022
  • Private Grant  awarded by Genentech 2019 - 2022
  • Private Grant  awarded by INCYTE CORPORATION 2017 - 2022
  • Private Grant  awarded by FATE THERAPEUTICS, INC. 2017 - 2021
  • Private Grant  awarded by EPIZYME - NEW 2016 - 2021
  • Private Grant  awarded by JUNO THERAPEUTICS 2016 - 2021
  • Private Grant  awarded by JUNO THERAPEUTICS 2016 - 2021
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2016 - 2021
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2021
  • Private Grant  awarded by MedImmune 2010 - 2020
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2013 - 2020
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2015 - 2020
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2020
  • Molecular Characterization of Myeloma and Related Asymptomatic Precursor States  awarded by National Cancer Institute/NIH/DHHS 2014 - 2020
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2018 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University 2015 - 2020
  • Private Grant  awarded by Genentech 2018 - 2020
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2015 - 2020
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2014 - 2019
  • BMT CTN 1302- Multicenter Phase II, Double Blinded, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma  awarded by National Marrow Donor Program 2017 - 2019
  • Prospective Observation of Cardiac Safety with Proteasome Inhibition (PROTECT)  awarded by VANDERBILT UNIVERSITY 2017 - 2019
  • Private Grant  awarded by FATE THERAPEUTICS, INC. 2016 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2018
  • Private Grant  awarded by Genentech 2015 - 2018
  • Private Grant  awarded by Gilead Sciences 2013 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2017 - 2018
  • Private Grant  awarded by INCYTE CORPORATION 2013 - 2018
  • Private Grant  awarded by PHARMACYCLICS, INC. 2015 - 2018
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2014 - 2018
  • Private Grant  awarded by Genentech 2016 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2014 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2016 - 2017
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2017
  • Private Grant  awarded by ARRAY BIOPHARMA 2015 - 2016
  • Private Grant  awarded by GlaxoSmithKline 2013 - 2016
  • Private Grant  awarded by MedImmune 2012 - 2016
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2011 - 2015
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2014
  • Education And Training

  • Doctor of Philosophy in Cell / Cellular Biology and Anatomical Sciences, University of Sao Paulo 2007
  • Doctor of Medicine, University of Sao Paulo 1999
  • University of Sao Paulo, Internship 2000
  • Wayne State University Program, Residency 2008
  • University of Sao Paulo, Residency 2003
  • Mayo Clinic, Postdoctoral Fellowship 2007
  • University of Colorado Aurora, Postdoctoral Fellowship 2006
  • Full Name

  • Luciano Costa